1. Citiranje strokovne literature v medicini : vancouvrski način citiranjaDavid Ožura, 2024, strokovni članek Povzetek: Strokovno besedilo, ki temelji na znanstvenoraziskovalnem delu, se od drugih besedil loči z doslednim sklicevanjem na ustrezne vire. V pričujočem prispevku si bomo podrobneje ogledali vancouvrski način citiranja, saj se ta slog sklicevanja najpogo-steje uporablja v medicini in zdravstvenih vedah. Predstavljeni so najpogostejši primeri navajanja osnovnih bibliografskih podatkov prispevkov v strokovnih revijah, posamičnih pri-spevkov v zbornikih, navajanja monografij ter informacijskih virov na internetu. Podani so osnovni napotki za označevanje, reproduciranje in citiranje tabel in slik s primeri. Na kratko so predstavljena tudi sodobna orodja za urejanje referenc in citiranja z njihovimi funkcionalnostmi. Ključne besede: citiranje literature, znanstvene revije, medicina, vancouvrski način citiranja, orodja za organizacijo referenc in citranja, navajanje in označevanje tabel in slik, onkologija Objavljeno v DiRROS: 26.07.2024; Ogledov: 227; Prenosov: 169 Celotno besedilo (3,01 MB) Gradivo ima več datotek! Več... |
2. Mobocertinib in patients with EGFR exon 20 insertion-positive non-small cell lung cancer (MOON) : an international real-world safety and efficacy analysisOliver Illini, Felix Carl Saalfeld, Petros Christopoulos, Michaël Duruisseaux, Anders Vikström, Nir Peled, Ingel Demedts, Elizabeth Dudnik, Anna Eisert, Urška Janžič, Katja Mohorčič, Marija Ivanović, Sayed M. S. Hashemi, 2024, izvirni znanstveni članek Povzetek: EGFR exon 20 (EGFR Ex20) insertion mutations in non-small cell lung cancer (NSCLC) are insensitive to traditional EGFR tyrosine kinase inhibitors (TKIs). Mobocertinib is the only approved TKI specifically designed to target EGFR Ex20. We performed an international, real-world safety and efficacy analysis on patients with EGFR Ex20-positive NSCLC enrolled in a mobocertinib early access program. We explored the mechanisms of resistance by analyzing postprogression biopsies, as well as cross-resistance to amivantamab. Data from 86 patients with a median age of 67 years and a median of two prior lines of treatment were analyzed. Treatment-related adverse events (TRAEs) occurred in 95% of patients. Grade ≥3 TRAEs were reported in 38% of patients and included diarrhea (22%) and rash (8%). In 17% of patients, therapy was permanently discontinued, and two patients died due to TRAEs. Women were seven times more likely to discontinue treatment than men. In the overall cohort, the objective response rate to mobocertinib was 34% (95% CI, 24–45). The response rate in treatment-naïve patients was 27% (95% CI, 8–58). The median progression-free and overall survival was 5 months (95% CI, 3.5–6.5) and 12 months (95% CI, 6.8–17.2), respectively. The intracranial response rate was limited (13%), and one-third of disease progression cases involved the brain. Mobocertinib also showed antitumor activity following EGFR Ex20-specific therapy and vice versa. Potential mechanisms of resistance to mobocertinib included amplifications in MET, PIK3CA, and NRAS. Mobocertinib demonstrated meaningful efficacy in a real-world setting but was associated with considerable gastrointestinal and cutaneous toxicity. Ključne besede: medicina, non-small cell lung cancer, EGFR exon 20 inhibitors, mobocertinib, real-world data, exon 20 insertion Objavljeno v DiRROS: 19.06.2024; Ogledov: 242; Prenosov: 147 Celotno besedilo (1,93 MB) Gradivo ima več datotek! Več... |
3. Spremljanje bolnic z ginekološkimi raki po zaključenem zdravljenjuDarja Arko, 2024, objavljeni strokovni prispevek na konferenci Povzetek: Število žensk, ki so se zdravile zaradi ginekoloških rakov, se veča zaradi staranje populacije, zgodnjega odkrivanja bolezni in bolj uspešnih načinov zdravljenja. Rak in zdravljenje raka prizadenejo ženske na več nivojih, fizično in psihično. Najpogostejše težave so kronične bolečine, utrujenost, limfedem, nevropatija, anksioznost in depresija. Ginekološki raki in njihovo zdravljenje imajo dodatno še pomemben negativen vpliv tudi na spolno življenje. Spremljanje bolnic po zdravljenju raka zato ni namenjeno samo zgodnjemu odkrivanju morebitne ponovitve bolezni, ampak tudi zagotavljanju čim boljše kakovosti življenja. Pomembno in potrebno je, da pri bolnicah po zdravljenju ginekoloških rakov prepoznamo in lajšamo težave, ki so posledica bodisi bolezni same ali pa posledica zdravljenja raka. Načini in organizacija spremljanja bolnic z ginekološkimi raki se močno razlikuje med posameznimi centri in državami, jasnih dokazov, kateri je najboljši način dela, ni. Verjetnost ponovitve bolezni se razlikuje glede na vrsto raka, stadij bolezni, stanje bolnice in glede na to, kako je bila zdravljena, zato je tudi spremljanje smiselno prilagoditi posameznici, kar poudarja večina sodobnih smernic. Ginekološki raki predstavljajo heterogeno skupino bolezni. Mednarodna in domača priporočila o spremljanju so narejena za posamezne lokalizacije in so na kratko predstavljena v prispevku. Ključne besede: rak (medicina), ginekologija, ponovitev bolezni, kakovost življenja, strokovna priporočila Objavljeno v DiRROS: 04.06.2024; Ogledov: 291; Prenosov: 83 Celotno besedilo (50,31 KB) |
4. CA19-9 serum levels predict micrometastases in patients with gastric cancerTomaž Jagrič, Stojan Potrč, Katarina Miš, Mojca Plankl, Tomaž Marš, 2016, izvirni znanstveni članek Povzetek: Background. We explored the prognostic value of the up-regulated carbohydrate antigen (CA19-9) in node-negative patients with gastric cancer as a surrogate marker for micrometastases. Patients and methods. Micrometastases were determined using reverse transcription quantitative polymerase chain reaction (RT-qPCR) for a subgroup of 30 node-negative patients. This group was used to determine the cut-off for preoperative CA19-9 serum levels as a surrogate marker for micrometastases. Then 187 node-negative T1 to T4 patients were selected to validate the predictive value of this CA19-9 threshold. Results. Patients with micrometastases had significantly higher preoperative CA19-9 serum levels compared to patients without micrometastases (p = 0.046). CA19-9 serum levels were significantly correlated with tumour site, tumour diameter, and perineural invasion. Although not reaching significance, subgroup analysis showed better five-year survival rates for patients with CA19-9 serum levels below the threshold, compared to patients with CA19-9 serum levels above the cut-off. The cumulative survival for T2 to T4 node-negative patients was significantly better with CA19-9 serum levels below the cut-off (p = 0.04). Conclusions. Preoperative CA19-9 serum levels can be used to predict higher risk for haematogenous spread and micrometastases in node-negative patients. However, CA19-9 serum levels lack the necessary sensitivity and specificity to reliably predict micrometastases. Ključne besede: gastric cancer, micrometastases, CA19-9, rak (medicina), želodec, metastaze, diagnostika, antigeni, tumorski označevalci Objavljeno v DiRROS: 09.05.2024; Ogledov: 298; Prenosov: 237 Celotno besedilo (793,76 KB) Gradivo ima več datotek! Več... |
5. Optimal scan time for evaluation of parathyroid adenoma with [18F]-fluorocholine PET/CTSebastijan Rep, Luka Ležaič, Tomaž Kocjan, Marija Pfeifer, Mojca Jensterle Sever, Urban Simončič, Petra Tomše, Marko Hočevar, 2015, izvirni znanstveni članek Ključne besede: lesions representing enlarged parathyroid tissue, triple-phase, standardized uptake value, retention index, lesion contrast, rak (medicina), obščitnični adenomi, diagnostika Objavljeno v DiRROS: 22.04.2024; Ogledov: 529; Prenosov: 423 Celotno besedilo (850,44 KB) Gradivo ima več datotek! Več... |
6. Distant metastasis of rectal adenocarcinoma in a temporary tracheostomaRobert Šifrer, Primož Strojan, Nina Zidar, Miha Žargi, Aleš Grošelj, Milena Krajinović, 2014, pregledni znanstveni članek Ključne besede: temporary tracheostoma, distant metastasis, rectal adenocarcinoma, rak (medicina), traheostoma, zasevki, metastaziranje, žlezni rak Objavljeno v DiRROS: 11.04.2024; Ogledov: 425; Prenosov: 210 Celotno besedilo (1,21 MB) Gradivo ima več datotek! Več... |
7. |
8. Clonality analysis of lymphoid proliferations using BIOMED-2 clonality assays : a single institution experienceIra Kokovič, Barbara Jezeršek Novaković, Petra Škerl, Srdjan Novaković, 2014, strokovni članek Ključne besede: onkologija, rak (medicina), limfom, diagnostika, analiza, molekularne metode, molekularna diagnostika Objavljeno v DiRROS: 10.04.2024; Ogledov: 368; Prenosov: 120 Celotno besedilo (899,82 KB) |
9. Consequence of the introduction of routine FCH PET/CT imaging for patients with prostate cancer : a dual centre surveyMarina Hodolič, Laure Michaud, V. Huchet, S. Balogova, V. Nataf, K. Kerrou, M. Vereb, Jurij Fettich, Jean-Noël Talbot, 2014, izvirni znanstveni članek Povzetek: Background. Fluorocholine(18F) (FCH) was introduced at the beginning of April 2010 in France, Slovenia and three other EU member states for the localisation of bone metastases of prostate cancer with PET. The aim of the study was to compare the evolution of diagnostic imaging in patients with prostate cancer using a new radiopharmaceutical FCH, observed in France and in Slovenia, and to quantify the consequence of the results of new imaging modality on the detection rate of abnormal metastases and recurrences of prostate cancer.Patients and methods. In two centres (France/Slovenia), a survey of the number of nuclear medicine examinations in patients with prostate cancer was performed, covering 5 quarters of the year since the introduction of FCH. For each examination, the clinical and biological circumstances were recorded, as well as the detection of bone or soft tissue foci.Results. Six hundred and eighty-eight nuclear medicine examinations were performed impatients with prostate cancer. Nuclear medicine examinations were performed for therapy monitoring and follow-up in 23% of cases. The number of FCH PET/CT grew rapidly between the 1st and 5th period of the observation (+220%), while the number of bone scintigraphies (BS) and fluoride(18F) PET/CTs decreased (-42% and -23% respectively). Fluorodeoxyglucose(18F) (FDG) PET/CT remained limited to few cases of castrate-resistant or metastatic prostate cancer in Paris. The proportion of negative results was significantly lower with FCH PET/CT (14%) than with BS (49%) or fluoride(18F) PET/CT (54%). For bone metastases, the detection rate was similar, but FCH PET/CT was performed on average at lower prostate-specific antigen (PSA) levels and was less frequently doubtful (4% vs. 28% for BS). FCH PET/CT also showed foci in prostatic bed (53% of cases) or in soft tissue (35% of cases).Conclusions. A rapid development of FCH PET/CT was observed in both centres and led to a higher detection rate of prostate cancer lesions. Ključne besede: prostate cancer, PET/CT, fluorocholine (FCH), fluoride(18F), bone scintigraphy, indication of imaging, prostata, rak (medicina), slikovna diagnostika Objavljeno v DiRROS: 04.04.2024; Ogledov: 751; Prenosov: 557 Celotno besedilo (595,04 KB) Gradivo ima več datotek! Več... |
10. Outcome of small cell lung cancer (SCLC) patients with brain metastases in a routine clinical settingMirko Lekić, Viljem Kovač, Nadja Triller, Lea Knez, Aleksander Sadikov, Tanja Čufer, 2012, izvirni znanstveni članek Povzetek: Background. Small cell lung cancer (SCLC) represents approximately 13 tomediansurvival of SCLC patients treated by specific therapy (chemotherapy andžor radiotherapy) with regard to the 18%months in patients treated with standard chemotherapy and radiotherapy. Inpresence or absence of brain metastases at the time of diagnosis. Patients and methods. All SCLC patients have been treated in a routine clinical practice and followed up at theUniversity Clinic Golnik in Slovenia. In the retrospective study the medical files from 2002 to 2007 were review. All patients with cytological or histological confirmed disease and eligible for specific oncological treatment were included in the study. They have been treated according to the guidelines valid at the time. Chemotherapy and regular followed-up were carried out at the University Clinic Golnik and radiotherapy at the Institute of Oncology Ljubljana. Results. We found 251 patients eligible for the study. The median age of them was 65 years, majoritywere male (67%), smokers or ex-smokers (98%), with performance status 0 to 1 (83%). At the time of diagnosis no metastases were found in 64 patients(25.5%) and metastases outside the brain were presented in 153 (61.0%). Brain metastases, confirmedby a CT scan, were present in 34 patients (13.5%), most of them had also metastases at other localisations. (Abstract truncated at 2000 characters) Ključne besede: pljuča, rak (medicina), drobnocelični rak, metastaze, možgani Objavljeno v DiRROS: 22.03.2024; Ogledov: 346; Prenosov: 122 Celotno besedilo (552,38 KB) |